Stelara for chronic moderate to severe psoriasis

February 2009

Canadians will be the first to be able to try Stelara for chronic moderate to severe psoriasis.

Stelara (ustekinumab) is a human monoclonal antibody.

It works by blocking interleukin IL-12 and IL-23. Most other biologics for psoriasis (Enbrel, Remicade, Humira) work differently. They block tumour necrosis factor.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

You'll see more patients with type 2 diabetes using insulin
Gastroenterology the dangers of sodium phosphate solutions for bowel prep
Neurology & Pain Health Canada to change the dose conversions from opioids to fentanyl patches
Interactions what to do when an antimicrobial is prescribed with warfarin
Women's Health Canadian guidelines will clarify some misconceptions about immunization during pregnancy
Women's Health fewer placebo pills with a new oral contraceptive called Yaz
Substance Use Disorder Instant cold packs are now being used to make methamphetamine
Rheumatoid Arthritis more aggressive use of disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis
Diabetes Patients with diabetes are asking if they should STOP taking a daily aspirin
Supplements People are getting lithium in the form of lithium orotate without a prescription
Supplements risks of using some supplements before or after surgery
Dermatology Stelara for chronic moderate to severe psoriasis
Practice significant new drugs approved by Health Canada in 2008 is ready for you

Stelara for chronic moderate to severe psoriasis

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents